Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.

@article{Brandt2003SixmonthRO,
  title={Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.},
  author={J. O. Brandt and Andre Khariouzov and Joachim Listing and Hildrun Haibel and H. F. K. S{\"o}rensen and L Grassnickel and Mart{\'i}n Rudwaleit and Joachim Sieper and J{\"u}rgen Braun},
  journal={Arthritis and rheumatism},
  year={2003},
  volume={48 6},
  pages={1667-75}
}
OBJECTIVE There is increasing evidence that tumor necrosis factor alpha (TNFalpha) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti-TNFalpha therapy with etanercept, a 75-kd receptor fusion protein, in active AS. METHODS This multicenter trial had 2 phases: an initial placebo-controlled period of 6 weeks' duration and an observational phase lasting 24 weeks. Thirty patients with… CONTINUE READING